close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Home・Aandelen Lijst・Harmony Biosciences Holdings Inc
Search

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

33.53 1.64

Strong Buy

Prijsupdate 12 nov 2025, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.48

Max

33.6

Belangrijke statistieken

By Trading Economics

Inkomsten

11M

51M

Verkoop

39M

239M

K/W

Sectorgemiddelde

10.038

105.69

EPS

1.08

Winstmarge

21.242

Werknemers

268

EBITDA

12M

71M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+42.11% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

145M

1.8B

Vorige openingsprijs

31.89

Vorige sluitingsprijs

33.53

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

29.8 / N/A Steun & Weerstand

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 nov 2025, 21:55 UTC

Winsten

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

DJ

Lezen

12 nov 2025, 21:34 UTC

Winsten

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

DJ

Lezen

12 nov 2025, 23:44 UTC

Marktinformatie

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

DJ

Lezen

12 nov 2025, 23:38 UTC

Marktinformatie

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

DJ

Lezen

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

DJ

Lezen

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

DJ

Lezen

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

DJ

Lezen

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

DJ

Lezen

12 nov 2025, 22:30 UTC

Marktinformatie
Winsten

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

DJ

Lezen

12 nov 2025, 22:18 UTC

Winsten

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

DJ

Lezen

12 nov 2025, 22:12 UTC

Marktinformatie

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

DJ

Lezen

12 nov 2025, 22:05 UTC

Winsten

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

DJ

Lezen

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

DJ

Lezen

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q Adj EPS 48c >PAAS

DJ

Lezen

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q Rev $884.4M >PAAS

DJ

Lezen

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q EPS 45c >PAAS

DJ

Lezen

12 nov 2025, 22:03 UTC

Winsten

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

DJ

Lezen

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q Net C$1.8B >MFC

DJ

Lezen

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q Adj EPS C$1.16 >MFC

DJ

Lezen

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q EPS C$1.02 >MFC

DJ

Lezen

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

DJ

Lezen

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

DJ

Lezen

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

DJ

Lezen

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

DJ

Lezen

12 nov 2025, 21:52 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

DJ

Lezen

12 nov 2025, 21:51 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

DJ

Lezen

12 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

DJ

Lezen

12 nov 2025, 21:49 UTC

Winsten

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

DJ

Lezen

12 nov 2025, 21:48 UTC

Winsten

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

DJ

Lezen

12 nov 2025, 21:40 UTC

Winsten

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

DJ

Lezen

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

42.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 45.22 USD  42.11%

Hoogste 62 USD

Laagste 32 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

0

Hold

1

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

29.8 / N/ASteun & Weerstand

Korte Termijn

Weak Bullish Evidence

Bullish events outweigh bearish events.

Gemiddeld Termijn

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Lange Termijn

Very Strong Bearish Evidence

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,017.74

↑ +3%

JNJ

Johnson and Johnson

194.37

↑ +0.29%

ABBV

AbbVie Inc

233.26

↑ +3.63%

UNH

UnitedHealth Group Inc

339.07

↑ +3.56%

AZN

AstraZeneca PLC ADR

87.67

↓-1.55%
help-icon Live chat